Rational Systemic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA)
Full Description
The successful development of an HIV vaccine with novel adjuvants depends on the selection of the most appropriate immunogen-adjuvant formulations. The R-CASA contract, which is focused on HIV vaccine development, will provide an opportunity to develop new approaches to assess optimal HIV immunogens-adjuvants formulations prior to transitioning into clinical trials. R-CASA will 1) generate and propose standardized protocols and endpoint assays for rational and systematic down-screening of HIV immunogen-adjuvant formulations, 2) apply those protocols and assays to screen HIV immunogen-adjuvant formulations, and 3) screen additional immunogens and adjuvants at the direction of NIAID. These efforts will delineate a standardized set of assays for biochemical and immunological characterization of HIV immunogen-adjuvant formulations, down-selection workflow, and go-no-go criteria to maximize the successful transition of immunogen-adjuvant formulations from the pre-clinical testing to First in-Humans (FIH) trials.
Grant Number: 75N93024C00053-P00003-9999-1
NIH Institute/Center: NIH
Principal Investigator: Arnab Chatterjee
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click